

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

**OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to Shanghai Junshi Biosciences Co., Ltd.: Announcement in Relation to Change in the Largest Shareholder of Shanghai Junshi Biosciences Co., Ltd. dated 26 June 2019 published by Shanghai Junshi Biosciences Co., Ltd. on the website of the National Equities Exchange and Quotations, for reference purpose only.

By order of the Board of  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 26 June 2019

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.*

\* For identification purpose only

Stock code: 833330

Stock abbreviation: Junshi Biosciences

Chief agency broker: CICC

**上海君實生物醫藥科技股份有限公司**  
**Shanghai Junshi Biosciences Co., Ltd.\***

**ANNOUNCEMENT IN RELATION TO  
CHANGE IN THE LARGEST SHAREHOLDER**

**The Company and all members of the Board of Directors warrant that this is a true, accurate and complete announcement, and there are no false representations and misleading statements contained in, or material omissions from, this announcement, and severally and jointly accept the responsibility for the truthfulness, accuracy and completeness of the contents of this announcement.**

**I. BASICS OF THE CHANGE**

**(I) Subject of the change**

☒ Change in the largest shareholder      ☐ Change in the controlling shareholders  
☐ Change in the de facto controllers      ☐ Change in the parties acting in concert

**(II) Way of change**

Mr. Xiong Jun transferred his equities through after-hours agreement, which led to the change in the largest shareholder of the listed company from Xiong Fengxiang to Xiong Jun. There are no additional parties acting in concert.

**II. BASICS OF THE LARGEST SHAREHOLDER AFTER THE CHANGE**

**(I) To be completed by natural person**

Name	Xiong Jun	
Nationality	China	
Right of permanent overseas residency	No	Nil
Work units and positions in the last five years	<p>He served as an executive director of Shanghai Baoying Asset Management Co., Ltd.* (上海寶盈資產管理有限公司) from February 2007 to date; chairman of Shanghai Union Biopharm Co., Ltd.* (上海眾合醫藥科技有限公司) (“Shanghai Union Limited”) and Shanghai Union Biopharm Biosciences Co., Ltd.* (上海眾合醫藥科技股份有限公司) (“Shanghai Union Biopharm”, which was merged with Junshi Biosciences by absorption in June 2016) from March 2013 to November 2015;</p>	

\* For identification purpose only

	general manager of Shanghai Union Limited and Shanghai Union Biopharm from September 2013 to November 2015; chairman of Shanghai Junshi Biosciences Co., Ltd.* (“Junshi Biosciences”) from May 2015 to date and concurrently served as a general manager of Junshi Biosciences from January 2016 to January 2018.	
Main business of the current unit	Shanghai Baoying Asset Management Co., Ltd.* : asset entrusted management (except financial business), M&A and asset restructuring planning, investment management, investment consulting, business consulting (except broker). Junshi Biosciences: R&D and industrialization of monoclonal antibody drugs and other therapeutic protein drugs, technical services and technology transfer for monoclonal antibody drug development, etc.	
Place of registration of the current unit	Shanghai	
Ownership relationship with the current unit	Yes	Holds 20% shareholding in Shanghai Baoying Asset Management Co., Ltd.*; directly held <u>8.01%</u> shares of Junshi Biosciences
Whether a director, supervisor or senior management of the listed company	Yes	
Whether an untrustworthy joint punishment object	No	—

### III. REASONS FOR THE CHANGE IN THE LARGEST SHAREHOLDER AND ITS IMPACT ON THE LISTING COMPANY

In order to promote the stability of the shareholding structure of the Company and achieve its comprehensive competitiveness, and given the confidence in the future development of the Company, Mr. Xiong Jun increased his holding by 12,500,000 shares in the listed company through the after-hours agreement. After the increase, Mr. Xiong Jun held a total of 62,839,968 shares and became the largest shareholder of the Company. Upon the increase, the largest shareholder of the Company was changed from Xiong Fengxiang to Xiong Jun, but Xiong Fengxiang and Xiong Jun are still the controlling shareholders and de facto controllers of the Company, and the aggregate shareholding of Xiong Fengxiang, Xiong Jun and parties acting in concert with them increased to 24.94%. The transaction will further enhance the control of the controlling shareholders and de facto controllers and will have no material adverse impact on the operations of the Company.

### IV. OTHER MATTERS

\* For identification purpose only

**(I) Information disclosure**

If the change constitutes an acquisition	<input type="checkbox"/> No	
If yes, if relevant information is disclosed	Not applicable	-
If a change in equity is triggered due to the change	No	
If yes, if relevant information is disclosed	Not applicable	-

**(II) Approval of relevant state departments**

If approval from relevant state departments are required for the change	No	
Approval department	Not applicable	
Approval procedure	Not applicable	
Progress of approval procedure	Not applicable	

**(III) Lock-up**

Mr. Xiong Jun is the chairman of the Company. According to the relevant provisions of the Company Law and National Equities Exchange and Quotations, partial shares that he additionally held must be locked up. Upon completion of the transaction, the Company will handle the lock-up in a timely manner.

**(IV) Others**

As of the date of this announcement, the relevant information on the change has been truthfully disclosed in accordance with relevant regulations, and there are no other significant information that should be disclosed according to the law and relevant regulations.

**V. LIST OF DOCUMENTS AVAILABLE FOR INSPECTION**

(I) a copy of proof of identity of Xiong Jun

The Board of Directors  
Shanghai Junshi Biosciences Co., Ltd.\*  
26 June 2019

\* For identification purpose only